Drugs & TargetsFree Ionis gets $28 million from AstraZeneca for new cancer drug January 06, 2017Vol.43 No.01
Drugs & TargetsFree MaxCyte, Washington University in St. Louis announce collaboration January 06, 2017Vol.43 No.01
Drugs & TargetsFree MD Anderson, Affimed collaborate on immunotherapy combination January 06, 2017Vol.43 No.01
Drugs & Targets Keytruda becomes first anti-PD-1 therapy to receive a CHMP positive opinion for previously untreated NSCLC December 16, 2016Vol.42 No.46
Drugs & Targets Verastem licenses exclusive worldwide rights to develop and commercialize Infinity’s oncology product candidate duvelisib. December 11, 2016Vol.42 No.42
